KRT19 and lung carcinoma: Salem et al. (2017) reported a blood biomarker panel containing interleukin (IL)-1b, neutrophil count, and cytokeratin-19 antigen to predict lung cancer radiotherapy response. Saito et al. (2014) constructed a three-microRNA signature to predict responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma. Liu et al. (2019) identified a miRNA signature by an in vitro system to assess radiosensitivity for head and neck squamous cell carcinomas and validated this signature using the TCGA database (Ning et al., 2015).